EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Q linea AB (QLINEA) fair value: what the stock is really worth

As of Oct 15, 2026: fair value of Q linea AB SEK 13.38, price SEK 16.75, upside -20.1%, quality 34 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0025420714

QL Q linea AB logo Thin data Oct 4, 2026

Q linea AB

QLINEA · ST

Weak valuationQuality is weak on top of the rich price.

Our calculation puts a fair price 20% below what the stock costs today.

Low debt
Mixed vs. peers (4/8)
Fair value kr 13.38 · Overvalued (−20.1%)
Quality 34/100
Weak Growth (revenue 3y −4.6 %/yr in SEK)
Negative free cash flow
Narrow moat 8/100 · thin data
Insider activity 25/100
Thin data
⚠ Dilution
Watch Q linea AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 21,402 kr 14.85 Fair Value kr 13.38 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.

How to read this chart

60‑month range kr 14.85 – kr 21,402 · fair‑value band kr 8.83 – kr 16.72 · the kr 16.75 price screens above the kr 13.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 4, 2026.

Follow Q linea in your weekly email

Every Wednesday you see whether Q linea is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland.

Show moreShow less

It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert.

The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.

Stock analysis

Q linea AB (QLINEA) currently trades at kr 16.75, while our model-based Fair Value estimate is kr 13.38, 20.1% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 8.83 (bear) to kr 16.72 (bull), the price of kr 16.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Q linea AB reported revenue of 11.1M SEK in FY2025 versus 9.3M SEK in FY2021, a compound +4.4%/yr. Reported net income was −182M SEK in FY2025.

Key figures

Market cap 317M SEK (≈ $31.8M) · P/S ratio 22.4 · EPS (TTM) kr −5.99 · Return on equity −75.5% · Return on assets (EBIT) −93.8% · Operating margin −820% · Revenue (TTM) 14.4M SEK · Revenue growth (YoY) +209%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 49% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −20%, QLINEA screens richer than that median.

Fair Value models

Bear kr 8.83 Fair Value kr 13.38 Bull kr 16.72
Price kr 16.75 · Upside -20.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 8.92 kr 11.95 kr 17.84 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 8.92 kr 11.95 kr 17.84 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 71
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Momentum 20
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+369.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−91,170.0% (2020) → −1,622.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

QLINEA screens overvalued: fair value 20% below the price. Compare with Abbott Laboratories, →

Compare Q linea AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 328 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −20.1% · Below median
Profitability
Return on assets −49.4% · Bottom 25%
Growth and dividend
Revenue growth 209.3% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.09× · Cheapest 25%
P/S (12 months) 2.20× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 9
FUTURE (revenue growth)100 · sector 35
PAST (return on equity)0 · sector 16
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $282.60 $310.86 +10% vs QLINEA
Boston Scientific Corporation BSX $42.19 $46.41 +10% vs QLINEA
DexCom, Inc DXCM $84.11 $92.52 +10% vs QLINEA
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥166.00 ¥182.60 +10% vs QLINEA
GE HealthCare Technologies Inc GEHC $65.74 $70.37 +7% vs QLINEA
Edwards Lifesciences Corporation EW $85.78 $81.94 −4% vs QLINEA
Siemens Healthineers AG SHL €38.26 €35.19 −8% vs QLINEA
Abbott Laboratories, ABT $102.61 $74.79 −27% vs QLINEA
Medtronic plc MDT $91.93 $65.61 −29% vs QLINEA
Koninklijke Philips N.V PHIA €22.18 €15.23 −31% vs QLINEA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Q linea AB · Fair Value
kr 13.38 −20%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Q linea AB Fair Value". https://www.fairvalue-calculator.com/stock/QLINEA

Frequently asked questions

Is Q linea AB (QLINEA) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of kr 13.38 versus a price of kr 16.75, about −20% upside (overvalued).
What is the fair value of QLINEA?
Our model-based fair value for Q linea AB is kr 13.38 (as of Oct 4, 2026), built from audited fundamentals. The current price: kr 16.75.
What is the quality score of QLINEA?
Q linea AB has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Q linea AB (QLINEA)?
Our model-based price target is the fair value of kr 13.38 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario kr 8.83, optimistic scenario kr 16.72. It is a calculation from audited fundamentals, not an analyst target.
What is the Q linea AB stock forecast for 2026?
Our models put fair value at kr 13.38, about −20% upside versus a price of kr 16.75 (overvalued). Cautious scenario kr 8.83, optimistic scenario kr 16.72. The calculation is refreshed regularly with new filings.
What is the revenue of Q linea AB (QLINEA)?
Q linea AB reported trailing-twelve-month revenue of about 14.4M SEK (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Q linea AB (QLINEA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Q linea AB it is kr 13.38 per share (as of Oct 4, 2026), against a price of kr 16.75. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Q linea AB stock overvalued or undervalued in 2026?
As of Oct 4, 2026, QLINEA trades above its calculated fair value: price kr 16.75, fair value kr 13.38, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of QLINEA?
No. The price is what the market pays today (kr 16.75); the fair value is what the company's own numbers justify (kr 13.38). For Q linea AB the two are kr 3.37 per share apart. That gap is exactly why we show both numbers side by side.
How much is Q linea AB worth?
The market values Q linea AB at about 317M SEK (market capitalisation, as of Oct 4, 2026). Per share that is kr 16.75; our models calculate a fair value of kr 13.38 per share.
What do the bullish and bearish scenarios say about QLINEA?
Our models span a range for Q linea AB: cautious scenario kr 8.83, base kr 13.38, optimistic kr 16.72 per share (as of Oct 4, 2026, price kr 16.75). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Q linea AB (QLINEA)?
Balance-sheet figures for Q linea AB (as of Oct 4, 2026): return on equity −75.5%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is QLINEA from its 52-week high?
Q linea AB trades at kr 16.75, about 49% below its 52-week high of kr 33.15 and 13% above the low of kr 14.85 (as of Oct 15, 2026). Distance from the high says nothing about value: that is what the fair value of kr 13.38 is for.
Which stocks are comparable to Q linea AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Q linea AB stock attractive at the current price?
The data as of Oct 4, 2026: price kr 16.75, calculated fair value kr 13.38 (−20%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of QLINEA calculated?
We run Q linea AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 13.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.5 % above its aggregate fair value. Q linea AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Q linea AB (QLINEA)?
The closing price on Oct 15, 2026 was kr 16.75. Our model-based fair value is kr 13.38, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Q linea AB right now?
Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (kr 8.83 to kr 16.72) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Q linea AB

How large is the market capitalisation of Q linea AB (QLINEA)?
The market capitalisation of Q linea AB is 317M SEK (≈ $31.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Q linea AB (QLINEA)?
The price-to-sales ratio of Q linea AB is 22.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Q linea AB (QLINEA)?
Earnings per share at Q linea AB are kr −5.99. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Q linea AB (QLINEA)?
The return on equity (ROE) of Q linea AB is −75.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Q linea AB (QLINEA)?
On an EBIT basis the return on assets of Q linea AB is −93.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Q linea AB (QLINEA)?
The operating margin of Q linea AB is −820% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Q linea AB (QLINEA)?
Revenue at Q linea AB is growing +209% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Q linea AB (QLINEA) generate?
The free cash flow of Q linea AB is −170M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Q linea AB (QLINEA) hold?
Q linea AB holds more cash than debt, 250M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Q linea AB in the live analysis

One click puts Q linea AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.